A Secretory Leukocyte Protease Inhibitor Variant with Improved Activity against Lung Infection

      Research output: Research - peer-reviewArticle

      Published

      View graph of relations

      Secretory leukocyte protease inhibitor (SLPI) is an important respiratory tract host defense protein, which is proteolytically inactivated by excessive neutrophil elastase (NE) during chronic Pseudomonas infection in the cystic fibrosis (CF) lung. We generated two putative NE-resistant variants of SLPI by site-directed mutagenesis, SLPI-A16G and SLPI-S15G-A16G, with a view to improving SLPI’s proteolytic stability. Both variants showed enhanced resistance to degradation in the presence of excess NE as well as CF patient sputum compared with SLPI-wild type (SLPI-WT). The ability of both variants to bind bacterial lipopolysaccharides and interact with nuclear factor-κB DNA binding sites was also preserved. Finally, we demonstrate increased anti-inflammatory activity of the SLPI-A16G protein compared with SLPI-WT in a murine model of pulmonary Pseudomonas infection. This study demonstrates the increased stability of these SLPI variants compared with SLPI-WT and their therapeutic potential as a putative anti-inflammatory treatment for CF lung disease.

      Documents

      DOI

      Original languageEnglish
      Pages (from-to)669-676
      JournalMucosal Immunology
      Journal publication dateMay 2016
      Issue number3
      Volume9
      Early online date16 Sep 2015
      DOIs
      StatePublished - May 2016

      ID: 16243942